HOPA 2020: Encorafenib + Binimetinib Trends Toward Better Efficacy Than Dabrafenib + Trametinib for BRAF-Mutant Melanoma
Though not statistically significant, outcomes were consistent with clinical trials.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.